Showing results (1151-1160 of 1,611) with videos related to

Sort By:
Pageof 162
JAMA Oncology|April 5, 2024
Magnetic Resonance Imaging in Prostate Cancer Screening: A Systematic Review and Meta-AnalysisTamás Fazekas, Sung Ryul Shim, Giuseppe Basile, et al.
JAMA Oncology|March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsAranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
JAMA Oncology|September 19, 2024
Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical TrialAnand Swaminath, Sameer Parpia, Marcin Wierzbicki, et al.
JAMA Oncology|September 19, 2024
Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical TrialNaifei Chen, Chengfei Pu, Lingling Zhao, et al.
JAMA Oncology|September 19, 2024
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical TrialRandy F Sweis, Pablo Gajate, Rafael Morales-Barrera, et al.
JAMA Oncology|February 29, 2024
Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor-Positive Breast CancerJulieta Leone, Michael J Hassett, Rachel A Freedman, et al.
JAMA Oncology|March 7, 2024
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung CancerYoko Tsukita, Takehiro Tozuka, Kohei Kushiro, et al.
JAMA Oncology|February 15, 2024
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical TrialPeter W Szlosarek, Benjamin C Creelan, Thomas Sarkodie, et al.
JAMA Oncology|February 15, 2024
Response to 2 Induction Courses of Bacillus Calmette-Guèrin Therapy Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer: 5-year Follow-Up of a Phase 2 Clinical TrialAndrew B Katims, Jacob Tallman, Emily Vertosick, et al.
JAMA Oncology|November 22, 2023
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical TrialYusuke Okuma, Kaoru Kubota, Mototsugu Shimokawa, et al.
Pageof 162